3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other solid neoplasm
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Multiple Myeloma
11
Lymphoma
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
10
Neoplasm Metastasis
9
Leukemia
9
Neoplasms
8
Myelodysplastic Syndromes
8
Hodgkin Disease
8
Carcinoma, Non-Small-Cell Lung
8
Breast Neoplasms
8
Lymphoma, Non-Hodgkin
7
Leukemia, Myeloid, Acute
7
Carcinoma, Renal Cell
7
Prostatic Neoplasms
6
Melanoma
6
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
Recurrence
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Hematologic Neoplasms
5
Graft vs Host Disease
5
Advanced Cancer
5
Unspecified Adult Solid Tumor, Protocol Specific
4
Primary Myelofibrosis
4
Pancreatic Neoplasms
4
Neoplasms, Plasma Cell
4
Myeloproliferative Disorders
4
Lung Neoplasms
4
Leukemia, Myelomonocytic, Chronic
4
Leukemia, Myeloid, Chronic-Phase
4
Glioblastoma
4
Interventions
Cyclophosphamide
3
Topotecan
2
seclidemstat
1
pembrolizumab
1
pegylated granulocyte colony-stimulating factor
1
fludarabine phosphate
1
fludarabine
1
Sirolimus
1
Simvastatin
1
Mesna
1
Granulocyte Colony-Stimulating Factor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Sarcoma, Clear Cell
×
Sirolimus
×
Clear all
NCT01331135
2020-05-29
Aflac ST0901
Emory University
Phase 1
Completed
18 enrolled